Clinical Trials & Research
At CHI Saint Joseph Health Cancer Care Center at Flaget Memorial Hospital, we believe that all patients—whether newly diagnosed, advanced or late stage cancer—should be given every chance to fight the disease. That’s why we’re committed to bringing new hope to our Bardstown communities through cancer research and clinical trials.
As a patient, you have direct access to multiple clinical trials that could offer alternatives to standard treatments and more choices for care, while advancing medical research.
Participation in any study is voluntary, and your oncologist will talk with you about the potential benefits, risks and what to expect. All trials are held at our full-service cancer center, so you don’t have to travel far to access these promising options.
See our current list of studies at Flaget Memorial below, or search all open cancer clinical trials at our locations throughout Central Kentucky.
For more information, including how to participate, call 859.313.2960.
Current Cancer Clinical Trials in Bardstown
- HER2+ metastatic breast cancer
- Triple negative metastatic breast cancer
- Adjuvant therapy for triple negative breast cancer
- High risk HR+ positive stage II-III disease
- HR+ disease that has progressed after aromatase inhibitor
- Weight loss study for breast cancer patients diagnosed within the last year
- Second line treatment of squamous NSCLC
- First line therapy for resected NSCLC
- Adjuvant treatment of stage III colon cancer with DNA mismatch repair deficiency
- First line therapy for metastatic colon cancer with DNA mismatch repair deficiency
- Study looking at the financial impact of newly diagnosed stage IV colon cancer
- Stage III-IV BRAFv600e mutated melanoma
- Melanoma that has advanced after taking an Anti-PD1/L agent
- Newly diagnosed metastatic sarcoma in patients under the age of 50
- Stage IV or unresectable sarcoma
- First line treatment for newly diagnosed Multiple Myeloma
- Registry trial for newly diagnosed or newly recurrent myeloma
- Study looking at fertility after a cancer diagnosis in females of childbearing potential with newly diagnosed cancer.